Gateway to Think Tanks
来源类型 | Working Paper |
规范类型 | 报告 |
DOI | 10.3386/w22745 |
来源ID | Working Paper 22745 |
When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization | |
Leemore Dafny; Christopher Ody; Matthew Schmitt | |
发表日期 | 2016-10-17 |
出版年 | 2016 |
语种 | 英语 |
摘要 | Branded pharmaceutical manufacturers frequently offer "copay coupons'" that insulate consumers from cost-sharing, thereby undermining insurers' ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and 2010. To overcome endogeneity concerns, we exploit cross-state and cross-consumer variation in coupon legality. We find that coupons increase branded sales by 60+ percent, entirely by reducing the sales of bioequivalent generics. During the five years following generic entry, we estimate that coupons increase total spending by $30 to $120 million per drug, or $700 million to $2.7 billion for our sample alone. |
主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Antitrust ; Industry Studies |
URL | https://www.nber.org/papers/w22745 |
来源智库 | National Bureau of Economic Research (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/580419 |
推荐引用方式 GB/T 7714 | Leemore Dafny,Christopher Ody,Matthew Schmitt. When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization. 2016. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
w22745.pdf(557KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。